Expression of caveolin-1 in tooth germ, ameloblastoma and ameloblastic carcinoma.


Journal

Medicina oral, patologia oral y cirugia bucal
ISSN: 1698-6946
Titre abrégé: Med Oral Patol Oral Cir Bucal
Pays: Spain
ID NLM: 101231694

Informations de publication

Date de publication:
01 Mar 2021
Historique:
received: 09 07 2020
accepted: 03 09 2020
pubmed: 11 10 2020
medline: 3 3 2021
entrez: 10 10 2020
Statut: epublish

Résumé

The caveolin-1 protein (structural component of membrane caveolae) plays important roles in several biological functions, such as endocytosis, cell adhesion, and cell signaling. However, this protein has been associated with mechanisms of tumorigenesis in several neoplasms. The expression patterns and roles of caveolin-1 in the oral epithelium and in embryonic and odontogenic tumor tissues are still unclear. The expression of caveolin-1 was evaluated in samples of the normal gingival epithelium (n=7), human tooth germ (TG) (n=12), ameloblastoma (AM) (n=83), and ameloblastic carcinoma (AC) (n=9) by immunohistochemistry. Additionally, AM samples were analyzed by qRT-PCR and Western blot. Most TG (91.7%), AM (73.5%) and AC (100%) samples showed diverse patterns of immunohistochemical positivity for caveolin-1, while only one gingival sample was positive. The transcript levels of cav-1 were significantly upregulated by 14.9-fold in AM tissue (P = 0.0014) compared to those in normal gingival epithelial tissue, as shown by qRT-PCR. Presence of caveolin-1 protein was confirmed by Western blot analysis. The caveolin-1 immunoexpression patterns throughout the stages of TG show its importance during odontogenesis. The overexpression of caveolin-1 in AM and AC compared to its expression in normal gingival epithelium (adult tissue) suggests a possible role of caveolin-1 in protumoral events, but due to the similar immunoexpression observed in AM and AC, caveolin-1 may not necessarily participate in the malignant transformation process. However, future studies are needed to clarify and confirm these hypotheses.

Sections du résumé

BACKGROUND BACKGROUND
The caveolin-1 protein (structural component of membrane caveolae) plays important roles in several biological functions, such as endocytosis, cell adhesion, and cell signaling. However, this protein has been associated with mechanisms of tumorigenesis in several neoplasms. The expression patterns and roles of caveolin-1 in the oral epithelium and in embryonic and odontogenic tumor tissues are still unclear.
MATERIAL AND METHODS METHODS
The expression of caveolin-1 was evaluated in samples of the normal gingival epithelium (n=7), human tooth germ (TG) (n=12), ameloblastoma (AM) (n=83), and ameloblastic carcinoma (AC) (n=9) by immunohistochemistry. Additionally, AM samples were analyzed by qRT-PCR and Western blot.
RESULTS RESULTS
Most TG (91.7%), AM (73.5%) and AC (100%) samples showed diverse patterns of immunohistochemical positivity for caveolin-1, while only one gingival sample was positive. The transcript levels of cav-1 were significantly upregulated by 14.9-fold in AM tissue (P = 0.0014) compared to those in normal gingival epithelial tissue, as shown by qRT-PCR. Presence of caveolin-1 protein was confirmed by Western blot analysis. The caveolin-1 immunoexpression patterns throughout the stages of TG show its importance during odontogenesis.
CONCLUSIONS CONCLUSIONS
The overexpression of caveolin-1 in AM and AC compared to its expression in normal gingival epithelium (adult tissue) suggests a possible role of caveolin-1 in protumoral events, but due to the similar immunoexpression observed in AM and AC, caveolin-1 may not necessarily participate in the malignant transformation process. However, future studies are needed to clarify and confirm these hypotheses.

Identifiants

pubmed: 33037799
pii: 24151
doi: 10.4317/medoral.24151
pmc: PMC7980299
doi:

Substances chimiques

Caveolin 1 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

e238-e245

Références

Tumour Biol. 2016 Feb;37(2):1863-9
pubmed: 26323261
FASEB J. 2014 Sep;28(9):3823-31
pubmed: 24858278
Connect Tissue Res. 2002;43(2-3):232-7
pubmed: 12489165
Onco Targets Ther. 2017 Feb 14;10:819-835
pubmed: 28243118
Pathol Oncol Res. 2009 Jun;15(2):231-40
pubmed: 19096916
Pathol Res Pract. 2017 Jul;213(7):809-814
pubmed: 28554768
Int J Surg Pathol. 2016 Aug;24(5):410-8
pubmed: 27020375
Pathol Oncol Res. 2020 Oct;26(4):2105-2113
pubmed: 31907776
Biochem Biophys Res Commun. 1999 Mar 5;256(1):192-7
pubmed: 10066445
Med Oral Patol Oral Cir Bucal. 2017 May 1;22(3):e324-e332
pubmed: 28390135
Oral Surg Oral Med Oral Pathol Oral Radiol. 2019 Apr;127(4):309-317
pubmed: 30692057
Cell. 2011 Jul 8;146(1):148-63
pubmed: 21729786
Tumour Biol. 2014 Oct;35(10):9487-95
pubmed: 25123270
BMC Cancer. 2015 Jan 30;15:25
pubmed: 25633184
Int J Cancer. 2018 Nov 1;143(9):2092-2104
pubmed: 29524224
Turk Patoloji Derg. 2014;30(2):94-9
pubmed: 24782297
Int J Oncol. 2004 Feb;24(2):435-40
pubmed: 14719121
J Cancer Res Clin Oncol. 2017 Feb;143(2):321-328
pubmed: 27771795
Front Physiol. 2018 Jun 26;9:750
pubmed: 30013481
J Mol Histol. 2016 Jun;47(3):337-44
pubmed: 27075451
Nat Rev Cancer. 2015 Apr;15(4):225-37
pubmed: 25801618
J Cancer Res Ther. 2014 Oct-Dec;10(4):1082-7
pubmed: 25579558
Mol Cancer. 2016 Nov 16;15(1):71
pubmed: 27852311
Methods. 2001 Dec;25(4):402-8
pubmed: 11846609
Cancer. 2007 Apr 15;109(8):1523-31
pubmed: 17342767
Res Vet Sci. 2017 Aug;113:94-100
pubmed: 28918236
Med Oral Patol Oral Cir Bucal. 2017 May 1;22(3):e314-e323
pubmed: 28390134
Exp Cell Res. 2007 Apr 15;313(7):1307-17
pubmed: 17359972
J Oral Pathol Med. 2003 Sep;32(8):461-7
pubmed: 12901727

Auteurs

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH